AUSTIN, Texas, Feb. 13, 2025 /PRNewswire/ -- Superior HealthPlan ("Superior"), a leading managed care organization in Texas and a company of Centene Corporation (NYSE: CNC), announced it has been named a Best Place for Working Parents® for a fifth consecutive year. This designation is supported by Early Matters Greater Austin, a joint initiative from United Way for Greater Austin and E3 Alliance.
"Supporting working parents with family-friendly resources, policies, and benefits, continues to be a priority for our organization," said Mark Sanders, Superior HealthPlan president and CEO. "This designation signifies our commitment to that approach, one that I believe allows us to elevate our ability to provide quality healthcare to the nearly two million people we serve across Texas."
In 2019, Superior was one of the first organizations in Austin to be recognized as a Family-Friendly Workplace. Ever since, Superior has been named a Best Place for Working Parents®, adding multiple benefits aimed at further supporting employees:
To learn more about the designation, visit https://bestplace4workingparents.com/.
About Superior HealthPlan
Founded in 1999, Superior HealthPlan is a managed care company that delivers quality health care throughout Texas. Committed to transforming the health of the community, one person at a time, Superior supports active local involvement in all 254 Texas counties with 3,300 employees throughout the state. Superior is a company of Centene Corporation, a leading healthcare enterprise that is committed to helping people live healthier lives. More information on Superior can be found at www.SuperiorHealthPlan.com.
Last Trade: | US$27.06 |
Daily Change: | 0.88 3.36 |
Daily Volume: | 11,310,589 |
Market Cap: | US$13.290B |
July 29, 2025 July 25, 2025 April 25, 2025 February 24, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load